File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer

TitleA highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer
Authors
Issue Date2014
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca
Citation
European Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374 How to Cite?
AbstractAIM: Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy. METHODS: A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity. RESULTS: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC. CONCLUSION: The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/201052
ISSN
2015 Impact Factor: 6.163
2015 SCImago Journal Rankings: 3.152
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorChai, J-
dc.contributor.authorHowie, AF-
dc.contributor.authorCameron, DA-
dc.contributor.authorAnderson, RA-
dc.date.accessioned2014-08-21T07:10:56Z-
dc.date.available2014-08-21T07:10:56Z-
dc.date.issued2014-
dc.identifier.citationEuropean Journal of Cancer, 2014, v. 50 n. 14, p. 2367-2374-
dc.identifier.issn0959-8049-
dc.identifier.urihttp://hdl.handle.net/10722/201052-
dc.description.abstractAIM: Anti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy. METHODS: A prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2-5 years later following chemotherapy were assessed in relation to menstrual activity. RESULTS: The picoAMH assay had a limit of detection of 7.5 pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2 years after diagnosis (mean 522 ± 169 versus 8.9 ± 1.3 pg/ml, P<0.0001) with high predictive value for continuing menses or amenorrhoea for the subsequent 3 years. AMH was detectable in more women than using a previous assay (P=0.004). Other markers of the ovarian reserve (follicle-stimulating hormone (FSH), inhibin B) were also of discriminatory value but to lesser extents. This finding was validated in a second, independent cohort of women treated for eBC. CONCLUSION: The 10-fold increased assay sensitivity showed very clear distinction between groups based on ovarian activity with excellent prediction of future menses or amenorrhoea. This will improve assessment of post-chemotherapy ovarian function in women and may aid treatment decisions. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca-
dc.relation.ispartofEuropean Journal of Cancer-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleA highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer-
dc.typeArticle-
dc.identifier.emailChai, J: jchai@hkucc.hku.hk-
dc.identifier.authorityChai, J=rp00241-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ejca.2014.06.011-
dc.identifier.pmid25027307-
dc.identifier.pmcidPMC4166459-
dc.identifier.hkuros234827-
dc.identifier.hkuros253799-
dc.identifier.volume50-
dc.identifier.issue14-
dc.identifier.spage2367-
dc.identifier.epage2374-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats